- Email: [email protected]
CME Exam: Chronic Idiopathic Urticaria
Continuing Medical Education examination
Chronic Idiopathic Urticaria Instructions for category 1 Continuing Medical Education credit The American Academy of Allergy, Asthma & Immunology is accredited as a provider of Continuing Medical Education (CME) by the Accreditation Council for Continuing Medical Education. Test ID no.: jaip0040 Contact hours: 1.0 Expiration date: October 31, 2016. Category 1 credit can be earned by reading the text material and taking this CME examination online. For complete instruction, visit the Journal’s Web site at www.jaci-inpractice.org.
Learning objectives: 1. To recognize the pertinent characteristics of chronic idiopathic urticaria. 2. To review the available treatment options for chronic idiopathic urticaria refractory to conventional treatment with antihistamines. 3. To discuss the efficacy and safety of omalizumb in the treatment of refractory chronic idiopathic urticaria.
CME items Question 1. Approximately what percentage of patients with chronic idiopathic urticaria can have concomitant angioedema? A. 5% B. 10% C. 20% D. 40%
Question 4. Which of the following assessments is required before the initiation of omalizumab therapy in an otherwise healthy patient with chronic idiopathic urticaria? A. Pulmonary function tests. B. Total serum IgE level. C. Skin prick tests for environmental allergy. D. No assessments.
Question 2. Which of the following add-on agents has regulatory approval for the treatment of chronic idiopathic urticaria refractory to H1 antihistamines? A. Cyclosporine B. Hydroxychloroquine C. Omalizumab D. Dapsone Question 3. Which of the following is an approved dosing regimen for omalizumab in the treatment of chronic idiopathic urticaria refractory to antihistamines? A. Omalizumab 375 mg subcutaneously every 4 weeks. B. Omalizumab 300 mg subcutaneously every 4 weeks.
Question 5. Which of the following outcomes was observed during the phase III clinical trials evaluating the safety and efficacy of omalizumab in chronic idiopathic urticaria refractory to treatment with antihistamines? A. Symptoms of urticaria remained persistently suppressed even after discontinuation of omalizumab therapy. B. Similar treatment effects were observed regardless of patient’s background therapy at the time of randomization. C. Improvements in weekly itch severity score were not observed until after 8 weeks of treatment. D. Serious adverse events occurred 4 times more frequently among patients receiving omalizumab than among those receiving placebo.
C. Omalizumab 75 mg subcutaneously every 4 weeks. D. Omalizumab 150 mg subcutaneously every 2 weeks.
1005
Chronic Idiopathic Urticaria Instructions for category 1 Continuing Medical Education credit The American Academy of Allergy, Asthma & Immunology is accredited as a provider of Continuing Medical Education (CME) by the Accreditation Council for Continuing Medical Education. Test ID no.: jaip0040 Contact hours: 1.0 Expiration date: October 31, 2016. Category 1 credit can be earned by reading the text material and taking this CME examination online. For complete instruction, visit the Journal’s Web site at www.jaci-inpractice.org.
Learning objectives: 1. To recognize the pertinent characteristics of chronic idiopathic urticaria. 2. To review the available treatment options for chronic idiopathic urticaria refractory to conventional treatment with antihistamines. 3. To discuss the efficacy and safety of omalizumb in the treatment of refractory chronic idiopathic urticaria.
CME items Question 1. Approximately what percentage of patients with chronic idiopathic urticaria can have concomitant angioedema? A. 5% B. 10% C. 20% D. 40%
Question 4. Which of the following assessments is required before the initiation of omalizumab therapy in an otherwise healthy patient with chronic idiopathic urticaria? A. Pulmonary function tests. B. Total serum IgE level. C. Skin prick tests for environmental allergy. D. No assessments.
Question 2. Which of the following add-on agents has regulatory approval for the treatment of chronic idiopathic urticaria refractory to H1 antihistamines? A. Cyclosporine B. Hydroxychloroquine C. Omalizumab D. Dapsone Question 3. Which of the following is an approved dosing regimen for omalizumab in the treatment of chronic idiopathic urticaria refractory to antihistamines? A. Omalizumab 375 mg subcutaneously every 4 weeks. B. Omalizumab 300 mg subcutaneously every 4 weeks.
Question 5. Which of the following outcomes was observed during the phase III clinical trials evaluating the safety and efficacy of omalizumab in chronic idiopathic urticaria refractory to treatment with antihistamines? A. Symptoms of urticaria remained persistently suppressed even after discontinuation of omalizumab therapy. B. Similar treatment effects were observed regardless of patient’s background therapy at the time of randomization. C. Improvements in weekly itch severity score were not observed until after 8 weeks of treatment. D. Serious adverse events occurred 4 times more frequently among patients receiving omalizumab than among those receiving placebo.
C. Omalizumab 75 mg subcutaneously every 4 weeks. D. Omalizumab 150 mg subcutaneously every 2 weeks.
1005